Catalent (CTLT)
(Delayed Data from NYSE)
$55.92 USD
+0.12 (0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET
5-Strong Sell of 5 5
D Value C Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CTLT 55.92 +0.12(0.22%)
Will CTLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CTLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTLT
TAK or CTLT: Which Is the Better Value Stock Right Now?
Charles River (CRL) Forges Collaboration With Ship of Theseus
CTLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
Other News for CTLT
Goldman’s debt issuers stocks basket
Laughing Water Capital Q1 2024 Letter
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Healthcare M&A Volume Falls in Q1:24, According to Acquisition Data from LevinPro HC